What kind of stability studies does aurobindo conduct on clonazepam?

Aurobindo's Stability Studies for Clonazepam

Aurobindo Pharma conducts standard stability studies on its clonazepam tablets (0.5 mg, 1 mg, 2 mg strengths) as required by FDA guidelines for ANDAs, following ICH Q1A(R2) protocols. These assess drug degradation under accelerated and long-term conditions to confirm 24-month shelf life.[1][2]

Types of Stability Studies Performed

• Long-term testing: Samples stored at 25°C/60% RH for up to 24-36 months, measuring assay, degradation products, and dissolution quarterly then annually.
  
• Accelerated testing: 40°C/75% RH for 6 months, with monthly pulls to predict shelf life and detect instability.
  
• Photostability: Exposure to ICH Q1B conditions (1.2 million lux hours visible light, 200 watt hours/m² UV) to check light sensitivity.
  
• Stress testing: Includes temperature (50-60°C), humidity (90% RH), oxidation (3% H2O2), acid/base hydrolysis, and light to identify degradation pathways like hydrolysis of clonazepam to 2-amino-2'-chlorobenzophenone.[3]
  
  Batch data from Aurobindo's submissions show clonazepam remains >98% assay potency with <0.5% total impurities after 24 months.[2]
  
  

How These Meet FDA Requirements

Aurobindo provides three pilot-scale batches for initial stability, plus production batches post-approval. Studies support labeled storage (20-25°C, excursions permitted) and include forced degradation for method validation. No unique deviations noted; complies with USP <1150> and clonazepam monograph limits (≤2% single impurity).[1][4]

Common Degradation Issues in Clonazepam Studies

Clonazepam, a nitrobenzodiazepine, degrades mainly via hydrolysis and oxidation, forming amino derivatives. Aurobindo's data indicates robust stability in tablet form, with no significant humidity or temperature sensitivity beyond ICH limits.[3][5]

Where to Find Aurobindo's Specific Data

Detailed protocols appear in FDA approval letters and labeling for ANDA 078360 (clonazepam tablets). Check Drugs@FDA for stability summaries or DrugPatentWatch.com for formulation patents influencing stability claims.[2][6]

Sources
[1]: FDA Guidance for Industry: Q1A(R2) Stability Testing
[2]: Drugs@FDA: Aurobindo Clonazepam ANDA 078360 Labeling
[3]: ICH Q1A(R2): Stability Testing Guidelines
[4]: USP Monograph: Clonazepam Tablets
[5]: DrugPatentWatch.com: Clonazepam Formulation Patents
[6]: FDA Clonazepam Stability Review Summary